查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1616236

多种癌症早期检测市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Multi Cancer Early Detection Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 93 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球多种癌症早期检测市场价值为13 亿美元，预计2024 年至2032 年复合年增长率为14.8%。 。数据显示，早期检测可以将某些癌症类型的存活率提高高达 90%。提高公众意识正在推动多种癌症早期检测测试的采用。领先的製药和生物技术公司正在与诊断公司合作开发和推广 MCED 测试。

这些合作伙伴关係对于将新技术引入市场并确保其广泛接受至关重要。根据测试类型，NGS技术支援多种基因panel和LDT，从而能够对众多基因进行快速定序。其高通量、准确性和不断下降的成本奠定了其在 MCED 市场的主导地位。这些工具适用于多种癌症，为癌症诊断提供了显着的多功能性。

他们透过一次测试识别多种癌症类型的能力增强了他们在 MCED 市场的价值。开发基因组和 LDT 的公司已经在诊断领域占据了重要地位。他们对製药和生物技术领域的研发和策略联盟的关注巩固了他们在 MCED 领域的领导地位。基因组学和分子生物学的进步不断推动基因组和 LDT 的发展。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 13亿美元
预测值 47 亿美元
复合年增长率 14.8%

这种持续的创新使这些工具始终处于癌症检测的最前沿，并巩固了它们在 MCED 市场中的地位。多癌症早期检测市场依最终用途分为医院、诊断实验室和其他最终用户。 2023 年，医院占据市场主导地位，市占率为 48.2%。患者经常去医院进行常规健康检查、诊断和癌症筛检。

这使得医院成为将 MCED 测试整合到既定医疗保健工作流程中的理想场所。医院拥有多学科团队，包括肿瘤学家、病理学家、遗传学家和其他专家，他们协作解释和应用 MCED 测试结果。这种团队合作增强了早期检测工作并改进了治疗计划。 2023 年，北美在多癌症早期检测市场处于领先地位，收入达 5.189 亿美元。

对次世代定序（NGS）和液体活检技术的大量投资推动了这一主导地位。 FDA 对多项 MCED 测试的突破性设备指定强调了有利的监管环境，简化了这些测试的开发和批准。患者意识的提高和对早期癌症检测解决方案不断增长的需求进一步加强了该地区在全球多癌症早期检测市场的领导地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症盛行率增加
      • 高癌症检出率加上对有效癌症工具的需求不断增长
      • 癌症筛检中资料分析和人工智慧 (AI) 的进步
    • 产业陷阱与挑战
      • 多癌筛检检测费用高
  • 成长潜力分析
  • 监管环境
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 基因组、LDT 等
  • 液体活检

第 6 章：市场估计与预测：按最终用途分类，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊断实验室
  • 其他最终用户

第 7 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 8 章：公司简介

  • AnPac Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • EarlyDiagnostics
  • Elypta AB
  • EXACT SCIENCES CORPORATION
  • Freenome Holdings, Inc.
  • Genecast Biotechnology Co., Ltd.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • GUARDANT HEALTH, INC.
  • Illumina, Inc. (GRAIL, Inc.)
  • Micronoma, Inc.
  • Oncocyte Corporation
  • Roche Holdings, Inc (FOUNDATION MEDICINE, INC.)
  • SeekIn Inc.
  • Singlera Genomics Inc
简介目录
Product Code: 11171

The Global Multi Cancer Early Detection Market, valued at USD 1.3 billion in 2023, is projected to grow at a CAGR of 14.8% from 2024 to 2032. Campaigns and educational initiatives by governments and non-profits have increased public awareness about the importance of early cancer detection. Data shows that early detection can improve survival rates by up to 90% for certain cancer types. Improving public awareness is driving the adoption of multi-cancer early-detection tests. Leading pharmaceutical and biotechnology companies are collaborating with diagnostic firms to develop and promote MCED tests.

These partnerships are crucial for introducing new technologies to the market and ensuring their widespread acceptance. By test type, NGS technology supports several gene panels and LDTs, enabling the rapid sequencing of numerous genes. Its high throughput, accuracy, and declining costs have established its dominance in the MCED market. These tools are applicable to a wide range of cancers, offering significant versatility in cancer diagnostics.

Their ability to identify multiple cancer types from a single test enhances their value in the MCED market. Companies developing gene panels and LDTs have secured a significant position in the diagnostics field. Their focus on R&D and strategic alliances in the pharmaceutical and biotech sectors solidifies their leadership in the MCED domain. Advancements in genomics and molecular biology continue to evolve gene panels and LDTs.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$1.3 Billion
Forecast Value$4.7 Billion
CAGR14.8%

This ongoing innovation keeps these tools at the forefront of cancer detection and strengthens their position in the MCED market. The multi-cancer early detection market is segmented by end-use into hospitals, diagnostic laboratories, and other end-users. Hospitals dominated the market in 2023 with a market share of 48.2%. Patients frequently visit hospitals for routine health check-ups, diagnostics, and cancer screenings.

This makes hospitals ideal venues for integrating MCED tests into established healthcare workflows. Hospitals have multidisciplinary teams, including oncologists, pathologists, geneticists, and other specialists, who collaboratively interpret and apply MCED test results. This teamwork enhances early detection efforts and improves treatment planning. North America led the multi-cancer early detection market in 2023, generating revenues of USD 518.9 million.

Substantial investments in next-generation sequencing (NGS) and liquid biopsy technologies drive this dominance. A favorable regulatory landscape, highlighted by the FDA's breakthrough device designations for multiple MCED tests, streamlines their development and approval. Increased patient awareness and a growing demand for early cancer detection solutions further strengthen the region's leadership in the global multi-cancer early detection market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of cancer
      • 3.2.1.2 High cancer detection rate coupled with growing demand for effective cancer tools
      • 3.2.1.3 Advancements in data analytics and artificial intelligence (AI) utilized in cancer screening
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of multi-cancer screening test
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Gene panel, LDT, & others
  • 5.3 Liquid biopsy

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Diagnostic laboratories
  • 6.4 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
    • 7.3.7 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 AnPac Bio-Medical Science Co., Ltd.
  • 8.2 Burning Rock Biotech Limited
  • 8.3 EarlyDiagnostics
  • 8.4 Elypta AB
  • 8.5 EXACT SCIENCES CORPORATION
  • 8.6 Freenome Holdings, Inc.
  • 8.7 Genecast Biotechnology Co., Ltd.
  • 8.8 Guangzhou AnchorDx Medical Co., Ltd.
  • 8.9 GUARDANT HEALTH, INC.
  • 8.10 Illumina, Inc. (GRAIL, Inc.)
  • 8.11 Micronoma, Inc.
  • 8.12 Oncocyte Corporation
  • 8.13 Roche Holdings, Inc (FOUNDATION MEDICINE, INC.)
  • 8.14 SeekIn Inc.
  • 8.15 Singlera Genomics Inc